Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (otvorí nové okno)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Zdroj‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Označenie‎: PubMed 21602718

Identifikátor digitálneho objektu‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (otvorí nové okno)

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (otvorí nové okno)

Banan M.

Zdroj‎: Ann Hematol 2013;92(3):289-99.

Označenie‎: PubMed 23318979

Identifikátor digitálneho objektu‎: 10.1007/s00277-012-1671-3

https://www.ncbi.nlm.nih.gov/pubmed/23318979 (otvorí nové okno)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (otvorí nové okno)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Zdroj‎: Transfusion 2007;47(10):1830-6.

Označenie‎: PubMed 17880608

Identifikátor digitálneho objektu‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (otvorí nové okno)

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (otvorí nové okno)

Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP.

Zdroj‎: Blood 1996;87(3):887-92.

Označenie‎: PubMed 8562958

https://www.ncbi.nlm.nih.gov/pubmed/8562958 (otvorí nové okno)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (otvorí nové okno)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Zdroj‎: Iran J Blood Cancer 2009;1(4):147-50.

Označenie‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (otvorí nové okno)

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. (otvorí nové okno)

Karimi M, Cohan N, Pishdad P.

Zdroj‎: Hematology 2015;20(1):53-7.

Označenie‎: PubMed 24717020

Identifikátor digitálneho objektu‎: 10.1179/1607845414Y.0000000168

https://www.ncbi.nlm.nih.gov/pubmed/24717020 (otvorí nové okno)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (otvorí nové okno)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Zdroj‎: Int J Hematol 2012;95(1):51-6.

Označenie‎: PubMed 22180324

Identifikátor digitálneho objektu‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (otvorí nové okno)

Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. (otvorí nové okno)

Kosaryan M, Karami H, Zafari M, Yaghobi N.

Zdroj‎: Hemoglobin 2014;38(2):115-8.

Označenie‎: PubMed 24471558

Identifikátor digitálneho objektu‎: 10.3109/03630269.2013.869229

https://www.ncbi.nlm.nih.gov/pubmed/24471558 (otvorí nové okno)

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (otvorí nové okno)

Musallam KM, Taher AT, Cappellini MD, Sankaran VG.

Zdroj‎: Blood 2013;121(12):2199-212.

Označenie‎: PubMed 23315167

Identifikátor digitálneho objektu‎: 10.1182/blood-2012-10-408021

https://www.ncbi.nlm.nih.gov/pubmed/23315167 (otvorí nové okno)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (otvorí nové okno)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Zdroj‎: Sci Rep. 2022;12(1):2752.

Označenie‎: PubMed 35177777

Identifikátor digitálneho objektu‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (otvorí nové okno)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (otvorí nové okno)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Zdroj‎: Haematologica 2004;89(10):1172-8.

Označenie‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (otvorí nové okno)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (otvorí nové okno)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Zdroj‎: Arch Iran Med 2009;12(3):295-7.

Označenie‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (otvorí nové okno)

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (otvorí nové okno)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Zdroj‎: Eur J Haematol 1996;56(5):326-8.

Označenie‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 (otvorí nové okno)

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (otvorí nové okno)

Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R.

Zdroj‎: J Matern Fetal Med 1999;8(1):1-7.

Označenie‎: PubMed 10052837

Identifikátor digitálneho objektu‎: 10.1002/(SICI)1520-6661(199901/02)8:1<1::AID-MFM1>3.0.CO;2-O

https://www.ncbi.nlm.nih.gov/pubmed/10052837 (otvorí nové okno)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (otvorí nové okno)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Zdroj‎: Acta Haematol 2004;111(4):189-95.

Označenie‎: PubMed 15153710

Identifikátor digitálneho objektu‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (otvorí nové okno)

Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. (otvorí nové okno)

Makis AC, Chaliasos N, Hatzimichael EC, Bourantas KL.

Zdroj‎: Ann Hematol 2001;80(8):492-5.

Označenie‎: PubMed 11563599

https://www.ncbi.nlm.nih.gov/pubmed/11563599 (otvorí nové okno)

Fetal globin induction--can it cure beta thalassemia? (otvorí nové okno)

Perrine SP.

Zdroj‎: Hematology Am Soc Hematol Educ Program 2005:38-44.

Označenie‎: PubMed 16304357

Identifikátor digitálneho objektu‎: 10.1182/asheducation-2005.1.38

https://www.ncbi.nlm.nih.gov/pubmed/16304357 (otvorí nové okno)